EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Synthetic manipulation of the cancer-immunity cycle: CAR-T cell therapy

Nathan Singh, Marcela V Maus

Immunity · 2023-10 · 56 (10) · 2296-2310

DOI: 10.1016/j.immuni.2023.09.010 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Immunity, 2023-10. Verfasst von Nathan Singh und 1 weiteren Autor:innen. Beteiligte Einrichtung: Division of Oncology, Washington University in St Louis School of Medicine, St. Louis, MO 63110, USA. Electronic address: nathan.singh@wustl.edu. Hauptthemen laut MEDLINE: Receptors, Chimeric Antigen, Neoplasms. Die Arbeit wurde bisher 44-mal zitiert (Crossref) und nennt 148 Literaturangaben. Gefördert von: Damon Runyon Cancer Research Foundation, University of Pennsylvania, University of Washington.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Synthetic immunity to cancer has been pioneered by the application of chimeric antigen receptor (CAR) engineering into autologous T cells. CAR T cell therapy is highly amenable to molecular engineering to bypass barriers of the cancer immunity cycle, such as endogenous antigen presentation, immune priming, and natural checkpoints that constrain immune responses. Here, we review CAR T cell design and the mechanisms that drive sustained CAR T cell effector activity and anti-tumor function. We discuss engineering approaches aimed at improving anti-tumor function through a variety of mechanistic interventions for both hematologic and solid tumors. The ability to engineer T cells in such a variety of ways, including by modifying their trafficking, antigen recognition, costimulation, and addition of synthetic genes, circuits, knockouts and base edits to finely tune complex functions, is arguably the most powerful way to manipulate the cancer immunity cycle in patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, Chimeric AntigenNeoplasmsHumansImmunotherapy, AdoptiveReceptors, Antigen, T-CellCell- and Tissue-Based TherapyTumor Microenvironment

Substanzen

Receptors, Chimeric AntigenReceptors, Antigen, T-Cell

Autor:innen und Institutionen

  • Division of Oncology, Washington University in St Louis School of Medicine, St. Louis, MO 63110, USA. Electronic address: nathan.singh@wustl.edu.
  • Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA 02114, USA. Electronic address: mvmaus@mgh.harvard.edu.

Förderung

  • Damon Runyon Cancer Research Foundation
  • University of Pennsylvania
  • University of Washington

Zitieren

APA

Singh, N., & Maus, M. V. (2023). Synthetic manipulation of the cancer-immunity cycle: CAR-T cell therapy. Immunity, 56(10), 2296-2310. https://doi.org/10.1016/j.immuni.2023.09.010

Vancouver

Singh N, Maus MV. Synthetic manipulation of the cancer-immunity cycle: CAR-T cell therapy. Immunity. 2023;56(10):2296-2310. doi:10.1016/j.immuni.2023.09.010

BibTeX
@article{Singh2023,
  author = {Singh, Nathan and Maus, Marcela V},
  title = {Synthetic manipulation of the cancer-immunity cycle: CAR-T cell therapy},
  journal = {Immunity},
  year = {2023},
  volume = {56},
  number = {10},
  pages = {2296--2310},
  doi = {10.1016/j.immuni.2023.09.010}
}
Kostenlos starten →